Fields of application
In addition to the CE marked Oncogramme® DM-DIV for metastatic colorectal cancer, does Oncomedics offer other types of Oncogramme® (RUO)?
Oncomedics provides Oncogramme® for research purposes only (RUO).
Oncomedics may provide Oncogramme® for breast, ovarian, colon and glioblastoma cancers for research purposes.
Can the Oncogramme® only be used for first-line treatment?
The Oncogramme® DM-DIV has been CE marked for the first line treatment of metastatic colorectal cancer.
But the Oncogramme® can be used for other medical needs useful to oncologists (research, clinical research, etc.).
For all these other indications, the Oncogramme® does not have IVD approval. Oncomedics is open to discussion to help clinicians and research teams define new uses.
Can the Oncogramme® only study the effect of chemotherapy treatments (5-FU, FOLFOX, FOLFIRI)?
The Oncogramme® DM-DIV has been CE marked for the first line treatment of metastatic colorectal cancer.
Any molecule targeting tumour cells can be used, for example to assess the impact of therapeutic antibodies, kinase inhibitors, siRNAs, etc.
The Oncogramme® has been used and is used to test any molecule that targets tumour cells (Panitumumab, Cetuximab) in research programmes or clinical programmes for protocols including molecules other than chemotherapies.